Senior Director, Agentic AI and Automation at Acadia Pharmaceuticals

Conshohocken, Pennsylvania, United States

Acadia Pharmaceuticals Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, BiotechnologyIndustries

Requirements

  • Advanced degree (Ph.D. preferred) in AI, Data Science, Computer Science, Applied Mathematics, Engineering, Physics, or related field
  • 15+ years leading AI/ML or intelligent-automation initiatives
  • 10+ years hands-on with Python, SQL, R, MATLAB, PyTorch, Keras, Git
  • 12+ years architecting ML/deep-learning solutions including LLMs (GPT-4, BERT, LLaMA, Dolly) and RAG pipelines
  • 8+ years building web apps (Dash, Streamlit, Shiny) and advanced data products

Responsibilities

  • Define and execute a multi-year agentic AI & RPA roadmap converging hyperautomation, process-mining, and LLM-driven workflows
  • Operationalize an Agentic Automation Center of Excellence (CoE) governing standards, reusable assets, and ROI tracking
  • Partner with cross-functional executives to prioritize high-value automations across the business (clinical, commercial, PV, manufacturing)
  • Architect modular multi-agent systems powered by frontier LLMs and leading agent frameworks (LangChain family, AutoGen, CrewAI, etc.)
  • Design secure agent-to-agent (A2A) communication with shared memory, credential vaults, RBAC
  • Implement enterprise MCP engine and Agent Protocol standards enabling human–agent–bot collaboration
  • Standardize integration with vector stores and cloud MLOps platforms (Azure AI Search, Databricks, SageMaker, Vertex AI)
  • Build event-driven, low-code pipelines (n8n, Dify, Glean) to trigger agentic RPA tasks in real time
  • Implement observability and governance (Arcade.dev, AgentOps, Langfuse)
  • Establish robust testing harnesses and GxP-compliant validation for every autonomous workflow
  • Leverage process- & task-mining insights to auto-generate automation backlogs and measure value
  • Lead a multi-disciplinary squad of AI automation architects, prompt engineers, and product managers
  • Drive iterative product delivery using agile OKRs, rapid POCs, and continual KPI evaluation
  • Experiment with cutting-edge agent research (ReWOO, SuperAGI, CAMEL) and open-source Agentic RPA
  • Collaborate with open-source communities, cloud partners, and leading vendors
  • Set standards for agent safety, ethical AI, and closed-loop feedback
  • Forge deep partnerships with Enterprise Data, IT Infrastructure, and Cybersecurity teams
  • Champion MCP and agent-orchestration patterns for future-proof integration

Skills

Agentic AI
RPA
Process Mining
LLM
Hyperautomation
Generative AI
AI Orchestration
Systems Thinking

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI